Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: changedmyname who wrote (85561)	7/20/1999 2:50:00 PM
From: Rock_nj	Read Replies (1) \| Respond to of 119973

USAB bottoming out in the lows 11s? Looking for a nice run next week with the site opening August 1st.

To: changedmyname who wrote (85561)	7/20/1999 2:51:00 PM
From: kendall harmon	Read Replies (2) \| Respond to of 119973

MXWL news is HUGE-their pulsating light system "deactivates" HIV Tuesday July 20, 8:17 am Eastern Time Company Press Release Independent Tests Confirm That Maxwell Technologies' Purebright Pulsed Light System Inactivates HIV, Other Viruses Joint Testing With Industry Partners to Target Blood Products, Biopharmaceuticals SAN DIEGO--(BW Healthwire)--July 20, 1999-- Maxwell Technologies Inc. (Nasdaq:MXWL - news) announced today that independent tests commissioned by Maxwell's PurePulse subsidiary confirm that its PureBright® proprietary pulsed light system inactivates HIV and other viruses that can contaminate blood products and biopharmaceuticals. Tom Horgan, Maxwell's chief executive officer, said that PurePulse has signed a confidential testing agreement with one company and is in discussions with others that have reviewed the independent test results and expressed interest in incorporating PureBright technology into their manufacturing and quality assurance processes. ''PureBright has inactivated every virus we have tested it against without the assistance of chemicals or any other treatment,'' Horgan said. ''We believe that it can meet a major public health need by providing a single, highly effective method for solving virus-related problems in a wide range of medical and pharmaceutical applications without impairing the therapeutic properties of the products.'' PurePulse commissioned Minnesota-based ViroMed Biosafety Laboratories to test the PureBright system against several different viruses, including HIV-1, bovine diarrhea virus, and two highly chemical-resistant viruses, SV40 and canine parvovirus. ViroMed found that PureBright inactivated both enveloped and non-enveloped viruses regardless of nucleic acid content, and was effective in the presence of serum proteins. Virus inactivation methods currently used in the blood products and pharmaceutical industries include heat, filtration and chemical treatments. However, no single process inactivates all viruses, and some viruses cannot be inactivated by any currently available process. The PureBright system uses broad spectrum light that is 90,000 times as intense as sunlight at sea level to destroy target RNA/DNA structures. PurePulse also is applying the PureBright technology to sterilize other medical products and product containers and to purify water. Ted Toch, president of PurePulse, noted that the blood products and biopharmaceutical industries have combined annual revenues of more than $11 billion, and that the ability to eliminate virus contamination represents a major commercial opportunity. ''We expect to begin joint laboratory testing at multiple locations within the next few months,'' Toch said. ''The next steps would be negotiation of commercial licenses, followed by extensive pilot-scale testing. Commercial application ultimately would be subject to regulatory approvals.''